| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6286620 | Progress in Neurobiology | 2011 | 19 Pages |
Abstract
- l-DOPA is the most potent drug for symptomatic treatment of Parkinson's disease.
- Its use is delayed by some doctors due to adverse and potentially toxic effects.
- This is a comprehensive review of l-DOPA effects on nigral dopaminergic neurons.
- Data are presented in the context of pathophysiology of Parkinson's disease.
- We critically discuss methodological limitations of in vivo and in vitro studies.
Keywords
1-methyl-4-phenylpyridiniumERKSNCDATAADCAMPAALDHMPTPCatechol-O-methyltransferaseNMDAGDNFα-amino-3-hydroxyl-5-methyl-4-isoxazole-propionateCOMTVTADOPACMAOVMATUPDRSBSON-methyl-d-aspartic acidJnkRRFMEADAergic6-OHDAl-buthionine-sulfoximineβ-CITUnited Parkinson's Disease Rating Scale3,4-dihydroxyphenylacetaldehyde6-Cyano-7-nitroquinoxaline-2,3-dionecyclic AMPBDNFc-Jun N-terminal kinasecAMPl-DOPAMAPKMPP+OH−ONOO−ROSTOPAAdenosine TriphosphateATPmulti-electrode arrayClinical trialsaldehyde dehydrogenasearomatic l-amino acid decarboxylaseDopamine transporterBaxParkinson's diseasesubstantia nigra pars compactatyrosine hydroxylaseVesicular monoamine transporterDopamineDopaminergicHydroxyl radicalretrorubral fieldLATSODToxicitySuperoxideSuperoxide dismutaseCNQXUbiquitin-proteasome systemendoplasmic reticulumDOPALglia-derived neurotrophic factorBrain-derived neurotrophic factorlevodopaCSFCerebrospinal fluidIn vitro studiesmonoamine oxidaseventral tegmental areaNitric oxideBcl-2-associated X proteinmitogen-activated protein kinasePeroxynitriteextracellular signal-regulated kinaseReactive oxygen speciesUPS
Related Topics
Life Sciences
Neuroscience
Neuroscience (General)
Authors
Janusz Lipski, Robert Nistico, Nicola Berretta, Ezia Guatteo, Giorgio Bernardi, Nicola B. Mercuri,